Drug Target Review

MARCH 24, 2025

Having previously drawn parallels with industry adoption of electronic lab notebooks in part 1 , this article expands on his vision for the future of the industry, sharing his forward-thinking ideas and practical recommendations. Currently, understanding these aspects requires extensive animal testing followed by human trials.

Clinical Trials 59

Clinical Trials Animal Testing Pharmacokinetics Drugs 59

Reprocell

NOVEMBER 1, 2022

Pharma companies are legally required to test novel drugs in animal models before beginning human trials. And while animal testing has progressed thousands of therapeutics that we use today, it is not without its experimental and ethical downfalls.

Animal Testing 52

Animal Testing Pharma Companies Laboratories Drug Development 52

Reprocell

MARCH 6, 2023

expands the range of models that can be used to test a compound before clinical trials. 1 Under this new law animal testing can still be used, but alternative testing methods now also represent a legitimate option. With support from over 200 organizations, the "FDA Modernization Act 2.0"

FDA 52

FDA Animal Testing Clinical Trials Trials 52

Agency IQ

JUNE 28, 2024

New guidance provides definition for orphan device, offers alternative trial designs New guidance from the European Commission outlines alternatives for full pre-market clinical trials for orphan devices, defined by the Commission for the first time. Data outside the PMCF (section 9.4) These data may help detect rare complications.

Trials 40

Trials Marketing Clinical Trials Disease 40

Vial

MAY 20, 2024

Distinguishing the Roles of Preclinical vs. Clinical CROs in Clinical Research Randomized clinical trials are the gold-standard of evidence-based medicine, representing the culmination of the long, arduous drug development pipeline.

Clinical Research 52

Clinical Research Clinical Trials Research Trials 52

The Pharma Data

JANUARY 11, 2021

Liver toxicity is a major safety concern during drug discovery and development, with the potential to terminate clinical trials and result in expensive program failures. Dr David Hughes, Chief Executive Officer, CN Bio, said : “This publication is invaluable in confirming the utility of our system in the labs of the FDA.

FDA 40

FDA Animal Testing Clinical Trials Pharmaceuticals 40

Codon

JULY 21, 2024

Xander Balwit offers concrete proposals for raising the welfare of animals used in biomedical research for our final article in Issue 03. It may seem that if researchers are sufficiently concerned about the welfare of lab animals, the best thing to do would be to stop using animals altogether.

Research 123

Research Engineering Disease Science 123